title: Trametinib, a first-in-class oral MEK inhibitor mass balance study with limited enrollment of two male subjects with advanced cancers.
abstract: 1. This study assessed the mass balance, metabolism and disposition of [(14)C]trametinib, a first-in-class mitogen-activated extracellular signal-related kinase (MEK) inhibitor, as an open-label, single solution dose (2 mg, 2.9 MBq [79 µCi]) in two male subjects with advanced cancer. 2. Trametinib absorption was rapid. Excretion was primarily via feces (∼81% of excreted dose); minor route was urinary (∼19% of excreted dose). The primary metabolic elimination route was deacetylation alone or in combination with hydroxylation. Circulating drug-related component profiles (composed of parent with metabolites) were similar to those found in elimination together with N-glucuronide of deacetylation product. Metabolite analysis was only possible from <50% of administered dose; therefore, percent of excreted dose (defined as fraction of percent of administered dose recovery over total dose recovered in excreta) was used to assess the relative importance of excretion and metabolite routes. The long elimination half-life (∼10 days) favoring sustained targeted activity was important in permitting trametinib to be the first MEK inhibitor with clinical activity in late stage clinical studies. 3. This study exemplifies the challenges and adaptability needed to understand the metabolism and disposition of an anticancer agent, like trametinib, with both low exposure and a long elimination half-life.
authors: Drug Metabolism and Pharmacokinetics, GlaxoSmithKline , King of Prussia, PA , USA .
authors: May Y K
authors: MY
authors: Ho
authors: Michael J
authors: MJ
authors: Morris
authors: Jill L
authors: JL
authors: Pirhalla
authors: John W
authors: JW
authors: Bauman
authors: Carolyn B
authors: CB
authors: Pendry
authors: Keith W
authors: KW
authors: Orford
authors: Royce A
authors: RA
authors: Morrison
authors: Donna S
authors: DS
authors: Cox
mesh_terms: D000042:Absorption; D000284:Administration, Oral; D000368:Aged; D000818:Animals; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D006528:Carcinoma, Hepatocellular / Q000188:drug therapy*; D004305:Dose-Response Relationship, Drug; D006801:Humans; D008113:Liver Neoplasms / Q000188:drug therapy*; D008297:Male; D008545:Melanoma / Q000188:drug therapy*; D008875:Middle Aged; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D011728:Pyridones / Q000737:chemistry / Q000627:therapeutic use*; D011744:Pyrimidinones / Q000737:chemistry / Q000627:therapeutic use*; D011874:Radiometry; D019275:Radiopharmaceuticals / Q000737:chemistry; D051381:Rats; D012878:Skin Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D047428:Protein Kinase Inhibitors; D011728:Pyridones; D011744:Pyrimidinones; D019275:Radiopharmaceuticals; C560077:trametinib